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Tumor metabolism has been the object of several studies in the past, leading to
the pivotal observation of a consistent shift toward aerobic glycolysis (so-called
Warburg effect). More recently, several additional investigations proved that tumor
metabolism is profoundly affected during tumorigenesis, including glucose, lipid and
amino-acid metabolism. It is noticeable that metabolic reprogramming can represent
a suitable therapeutic target in many cancer types. Epstein–Barr virus (EBV) was the
first virus linked with cancer in humans when Burkitt lymphoma (BL) was described.
Besides other well-known effects, it was recently demonstrated that EBV can induce
significant modification in cell metabolism, which may lead or contribute to neoplastic
transformation of human cells. Similarly, virus-induced tumorigenesis is characterized by
relevant metabolic abnormalities directly induced by the oncoviruses. In this article, the
authors critically review the most recent literature concerning EBV-induced metabolism
alterations in lymphomas.
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INTRODUCTION
Oncogenic viruses are an important public health issue since they are responsible for 20% of total
human cancer cases. The seven following viruses are currently considered proper human oncogenic
viruses: hepatitis B and C virus (HBV and HCV) account for approximately 80% of cases of
hepatocellular carcinoma (HCC) worldwide. Human papillomavirus (HPV, 16 and 18 especially) is
implied in cervical cancer, anogenital neoplasms, and head and neck tumors. Human herpes virus
8 (HHV8) is responsible for AIDS-related Kaposi’s sarcoma. Merkel cell polyomavirus (MCPyV),
causes Merkel cell carcinoma. HTLV-1 is the agent causing adult T-cell lymphoma. Epstein–Barr
virus (EBV), finally, is associated with many tumors including nasopharyngeal carcinoma (NPC)
and different lymphoma subtypes (Table 1; Luo and Ou, 2015).
These oncogenic viruses exert their oncogenic power by interfering with multiple molecular
signaling pathways. Sometimes they directly integrate their DNA in the host cell one [as does
HPV in cervical cancer cells (Fang et al., 2014) or HBV in hepatocytes inducing HCC development
(Herrmann et al., 1995)], some others they alter the expression of miRNAs (Ambrosio et al., 2014b),
and in other cases, they directly interact with proteins expressed by normal or cancer cells (this
is the most important pathogenetic way by which HCV induces HCC; Tsai and Chung, 2010).
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TABLE 1 | Association between oncoviruses and lymphomas.
Disease Oncovirus Experimentally proven
metabolic abnormality
Main Postulated
involved
oncogene
Reference
Post-transplant lymphoproliferative
disease
EBV No MYC Cesarman, 2011; Nourse et al., 2011
Diffuse large B-cell lymphoma∗ EBV No NF-kB Kanno et al., 1997; Dojcinov et al.,
2011; Kato et al., 2014
Burkitt lymphoma EBV Yes: increased import of key
nutrients, increased fatty acid
synthesis and glycolysis
MYC Yoon et al., 2007; Daye and Wellen,
2012; Dang, 2013; Eberlin et al., 2014;
Altman et al., 2016
Hodgkin lymphoma EBV No NF-kB Chapman and Rickinson, 1998;
Kuppers, 2009
Primary effusion lymphoma HHV-8+/EBV± No PI3K/AKT Okada et al., 2014; Mediani et al., 2016
Multicentric Castleman disease HHV-8+ No Not known Wang et al., 2016
Adult T-cell leukemia/lymphoma HTLV-1 No NF-kB Bangham and Ratner, 2015
EBV-positive T-cell lymphoproliferative
disorders
EBV No PI3K/AKT Anagnostopoulos et al., 1992; Ho et al.,
1999; Au et al., 2004; Zhou et al.,
2007; Cai et al., 2015
Adapted from “Immunodeficiency-associated viral oncogenesis” by A. Pierangeli, G. Antonelli and G. Gentile, 2015, Clinical Microbiology and Infection, Volume 21, Issue
11, 975 – 983. EBV, Epstein–Barr virus; HHV-8, human herpesvirus-8; HTLV-1, human T-cell lymphotropic virus type 1. ∗Not in the post-transplant setting. Based on the
expression of virus-encoded molecules proved to be an effect in experimental model.
Of these changes, certain ones may induce chronic
inflammation, and others can disrupt the cellular genetic
and epigenetic integrity (Fang et al., 2014) or interfere with
the host cell homeostasis and DNA repair mechanisms, thus
determining genome instability and deregulating the cell
cycle (Luo and Ou, 2015). Some of these changes are strictly
connected with metabolic dysfunction, such as enhanced
glucose uptake and glycolysis, dysregulation of molecular
pathways regulating oxidative stress, or alterations of lipid
metabolic expression patterns (Luo and Ou, 2015; Lo et al.,
2017).
The link between metabolic alterations and cancerogenesis,
even when not caused by oncogenic viruses, is still under
investigation. It is certain that the tumor cell goes through
a metabolic rearrangement, such as an augmented glucose
capture, and many metabolic patterns have proven to be
altered in cancer cells in linkage to oncogenes’ mutations
(Lo et al., 2017). A number of oncogenes, such as MYC,
hypoxia inducible factors-1 alpha subunit (HIF1A), and tumor
suppressor p53 (Yeung et al., 2008) as well as some pathways,
such as phosphoinositide 3-kinase (PI3K/AKT) and protein
kinase B (PKB), or the mammalian target of rapamycin
(MTORC1) one (Wieman et al., 2007), are known to be
involved in the energy metabolism regulation of cancer
cells.
The interaction between tumor and metabolism of the cell may
be direct, via the increase of nutrients that are available for tumor
growth (for example, by interacting with glucose transporters and
glycolytic enzymes). It may also be indirect, via the modulation
of cell proliferation pathways, such as the PI3K and mitogen-
activated protein kinase (MAPK), or stress response factors, such
as HIF1A and 5′ AMP-activated protein kinase (AMPK), that are
related to metabolic control (Chen and Russo, 2012; Noch and
Khalili, 2012).
The study of these mechanisms may be useful not only to fully
understand the pathogenesis of virus-induced tumors, but also to
widen the range of therapeutic options, combining anti-viral and
antiglycolytic or anti-lipid therapies in the cure of virus-driven
cancers.
In this review, we are going to focus on how EBV infected cells
are more likely to develop cancer. We will consider in particular
some types of cancers, and how metabolic dysregulation can be
one of the possible ways EBV employs to drive cancerogenesis in
these cells.
EPSTEIN–BARR VIRUS AND
CANCEROGENESIS
The EBV is a lymphocryptovirus of the γ-herpesvirus family.
It affects up to 90% of human adult population, typically
establishing a life-long persistent infection. It is considered a
group 1 carcinogen, according to the International Agency for
Research on Cancer, for its remarkable association with a large
variety of lymphoid and epithelial malignancies. According to
unadjusted estimates, nearly 3.7 million people are suffering
from EBV-driven cancers (de Martel et al., 2012). EBV has
been detected not only in Burkitt’s lymphoma (Navari et al.,
2015), in which the virus itself was discovered, and NPC, in
which it is almost always present, but it is also being related
to Hodgkin lymphoma, post-transplant lymphoproliferative
disorders (PTLD), T-cell non-Hodgkin lymphomas (NHL),
and gastric carcinomas. The evidence of association with
breast, HCCs, and smooth muscle cell-derived tumors in
immunodeficient individuals is less clear (Niedobitek et al.,
2001). Probably – since a pathogenetic role of EBV has been
demonstrated in so many cancers and the virus itself is so
widespread – it is not impossible to think that a certain
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percentage of cases of any type of cancer might conceal the
presence of EBV infection; nevertheless, B lymphocytes and
epithelial cells remain its preferential host cells.
The association with EBV can depend for most of these
tumors on geographical factors [e.g., Burkitt lymphoma (BL)],
histological subtype of the tumor (e.g., Hodgkin lymphoma), or
the cellular subtype infected (e.g., in T-cell lymphomas usually
only some of the cells are infected; Niedobitek et al., 2001).
The pathogenetic role of EBV in cancer development is
complex and yet not fully understood. An important role is for
sure played by latency products; these are expressed for the most
part of the virus lifetime, that is to say when the virus is not
in its lytic cycle replication, but in its latent phase. These affect
genes which are necessary for the immortalization of B-cells, by
permanently inducing the physiological molecular pathways that
lead to B-cell activation and cell division. These are the Epstein–
Barr nuclear antigen (EBNA) 1, 2, -LP, 3A, 3B, and 3C and the
latent membrane protein (LMP) 1, 2A, and 2B protein families.
Furthermore, two small (170 bases in length) non-polyadenylated
non-coding nuclear RNAs, the EBV encoded small RNAs 1 and 2
(EBER and EBER2), are abundantly expressed in latent infection,
up to 107 copies per cell (Niedobitek et al., 2001).
Based on how these genes are expressed in different
combinations in EBV-infected cells, three possible latency
patterns have been identified (Table 2).
Remarkably, recent evidence suggests that atypical latency
patterns are common, at least in lymphoid tumors (Abate
et al., 2015). Probably, the most commonly implicated in
cancerogenesis gene products are EBNA2 and LMP1 (Young and
Rickinson, 2004).
METABOLIC ALTERATIONS IN TUMORS
Cells can depend for their energy supply on two different major
pathways: oxidative phosphorylation and extra-mitochondrial
glycolysis. Usually, healthy and normally vascularized cells
tend to rely mostly on oxidative phosphorylation for ATP
synthesis, since this pathway is more effective in terms of
energy supply, while they tend to depend on glycolysis only
in conditions of hypoxia. In cancers, however, cells typically
TABLE 2 | Canonical EBV latency patterns.
Latency
I II III
EBERs + + +
EBNA1 + + +
EBNA2 − − +
EBNA3, A, B, C − − +
EBNA-LP − − +
LMP1 − + +
LMP2, A,B − + +
miRNAs BART miRNAs
(modest)
BART
miRNAs
(high)
BHRF1 miRNAs (high)
BART miRNAs
(modest)
tend to increase the extra-mitochondrial glycolysis. Even in the
presence of oxygen, they usually rely on this metabolic pathway
for ATP synthesis, rather than on oxidative phosphorylation.
This metabolic reprogramming process is known as the Warburg
effect (Warburg et al., 1927; Gatenby and Gillies, 2004). Not
only it allows malignant cells’ survival even in conditions of
hypoxia, but also it contributes to cell proliferation: the energy
that is not converted into ATP can in fact be shifted toward the
constitution of various macromolecules (proteins, nucleic acids,
and lipids), which are useful to the cell growth (Jones and Bianchi,
2015). Moreover, the decrease of oxidative phosphorylation also
probably leads to a less efficient reactive oxygen species (ROS)
production, such as hydrogen peroxide and superoxide anion,
which can be harmful to the cell or promote cellular senescence
(Kim and Dang, 2006).
Not only do cancer cells tend to use glucose differently from
normal cells, but they also need more of it for their rapid growth:
the number of glucose transporters on the cell membrane is
typically increased. The avid uptake of glucose by tumors is
the rationale for their detection by fluorodeoxyglucose positron
emission tomography (FDG-PET; Macheda et al., 2005).
Finally, lipid metabolism too has proven to be altered in many
cancer types: first, fatty acids, phospholipids, and cholesterol,
the three main lipid molecules of our cells, are significantly
increased and actively biosynthesized in tumor cells. Second,
choline kinase, an enzyme playing a key role in the biosynthesis
of phosphatidylcholine, is upregulated in multiple cancer cell
lines (Janardhan et al., 2006) and, third, active sterol biosynthesis
helps cell proliferation (Huang and Freter, 2015). Moreover, there
is a significant overexpression of genes involved in cholesterol
biosynthetic pathway in refractory tumors (Krycer and Brown,
2013; Huang and Freter, 2015).
Many findings suggest a correlation between EBV infection
and some of these metabolic alterations. During EBV infection,
the virus meets the amplified bioenergetic and biosynthetic
demands, by hijacking host cell metabolism to increase nutrient
uptake and anabolic metabolism. Doing this, it mirrors the
Warburg effect normally occurring in highly proliferating and
neoplastic cells. Nevertheless, unlike cancer cells, EBV undergoes
powerful selection for efficiency, and has the capacity to rapidly
and strongly reprogram host cell metabolism (Cuninghame et al.,
2014; Mesri et al., 2014; Pierangeli et al., 2015; Levy and Bartosch,
2016). Particularly, EBV can affect glucose and lipid metabolism,
while altering enzymatic functions (e.g., HIF1A and AMPK) and
inducing ROSproduction (Lo et al., 2017).
EBV-DRIVEN CARBOHYDRATE
METABOLIC ALTERATIONS IN
NASOPHARYNGEAL CARCINOMA (NPC)
Ninety-five percent of NPC cases in South China (where this
cancer is most commonly diagnosed) are of the histological type
III according to the WHO classification (undifferentiated type),
which is associated with EBV infection (Raab-Traub, 2002). In
the EBV-infected NPC cells, the most common latency program
is latency II type. This includes the expression of LMP1 and
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LMP2, EBNA1, EBERs, as well as some EBV-encoded miRNAs
(Table 2). Among these antigens, LMP1 is considered as a crucial
oncoprotein (Figure 1), as it is implicated in the maintenance
of latent infection and in the malignant transformation. LMP1
has also a role in the metastatic and local invasion, enhancing the
production of angiogenic factors, as well as in the processes linked
to inflammation and antigen presentation, which may favor the
tumor progression, but also its immune escape ability (Hitt et al.,
1989; Dawson et al., 2012). Myeloid-derived suppressor cells
(MDSCs) are key regulatory cells that have a role in this latter
process, as they are physiologically appointed to inflammation
control but are also able to favor immune escape (Cai et al., 2017).
The microenvironment of a wide range of tumors, including
NPC, has shown to be enriched in MDSCs. EBV may be
implied in their expansion, though it is not clear how yet. One
possible hypothesis is that LMP1 promotes MDSC expansion
by increasing the rate of extra-mitochondrial glycolysis in
cancer cells. This is consistent with the observation that a high
expression level of LMP1, glucose transporter 1 (GLUT1), and
CD33+MDSCs is frequently reported in NPC sections (Cai et al.,
2017).
Recent studies have confirmed that LMP1 prompts the
so-called “aerobic glycolysis” by inducing the expression of
multiple glycolytic genes, including GLUT1 and hexokinase 2
(HK2; Lo et al., 2015). One other way LMP1 increases GLUT1
levels is by blocking its K48-ubiquitination and p62-dependent
autolysosomal degradation, thus stabilizing the protein (Cai
et al., 2017). The increase in glucose consumption and in
the production of lactate suggests that the augmented glucose
avidity is almost entirely used to implement extra-mitochondrial
glycolysis.
This metabolic reprogramming induces an expansion of the
MDSC subset mainly by favoring some inflammatory pathways.
The expression of the Nod-like receptor family protein 3
(NLRP3) inflammasome is increased, as well as COX-2 and
P-p65 ones, so that their downstream cytokines (IL-1β, IL-6, and
GM-CSF) are also increased (Cai et al., 2017).
Other current findings have implied that LMP1 is also
involved in the fibroblast growth factor 2 and fibroblast growth
factor receptor 1 (FGF2/FGFR1) pathway activity, which can
also contribute to the increase of aerobic glycolysis in the EBV-
infected epithelial, and in turn lead them to evolve in NPC (Lo
et al., 2015).
Constitutive FGFR1 activation, due to mutation or
overexpression of FGFR1 or its ligands, is known to induce
cellular transformation and has been documented in a variety
of human malignancies (Kelleher et al., 2013). This activation
is common in NPC, especially in cases that are LMP1-positive,
FIGURE 1 | Role played by LMP1 in cancerogenesis.
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FIGURE 2 | Metabolic alterations induced in cancer cells by EBV infection and possible therapeutic targets.
i.e., the EBV-infected ones. With respect to these cases, LMP1
leads to the constitutive activation of the FGFR1 signaling
pathway, not only by increasing FGFR1 expression, but also
by upregulating FGF2 (Lo et al., 2017). The role of this
pathway in cancer transformation and growth is confirmed
by the fact that FGFR1 inhibitors attenuate both LMP1-
mediated aerobic glycolysis, reducing lactate dehydrogenase
A (LDHA) phosphorylation and activity in nasopharyngeal
epithelial cells, and cellular transformation, proliferation,
migration, and invasion (Kelleher et al., 2013; Lo et al.,
2015).
GLUT1 upregulation via MTORC1/nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) signaling
pathways is another main oncogenic pathway of EBV in NPC
cells (Wieman et al., 2007; Lo et al., 2017). MTORC1 is a
serine/threonine protein kinase pathway that is evolutionarily
conserved. It is involved in regulating energy metabolism and
cell growth by controlling protein translation and ribosome
biogenesis (Zhang et al., 2017). It is usually activated by
PI3K/AKT and other phosphorylating pathways. In EBV-
infected cells, LMP1 activates MTORC1 which, in turn,
upregulates the expression of GLUT1. C-terminal activating
region 2 (CTAR2) of LMP1 is probably the main domain
involved in MTORC1 activation, through an IKK-mediated
process (phosphorylation of TSC2 at Ser939; Zhang et al.,
2017).
It has been demonstrated that disrupting the activity of
MTORC1 signaling in EBV-driven NPC effectively suppresses
both LMP1-induced NF-kB activation and GLUT1 transcription.
On the other hand, blocking NF-kB signaling preserves MTORC1
activity but alters GLUT1 transcription. This result suggests that
GLUT1 is a direct target of NF-kB signaling (Lo et al., 2017; Zhang
et al., 2017).
LMP1 seems to be implied also in the process of DNA
damage response (DDR), especially when involved in radio-
resistance. HK2 expression levels are positively correlated to
LMP1 expression in NPC tissues, and they are associated with
poor survival rates after tumor radiation (Xiao et al., 2014; Lo
et al., 2017). In particular, LMP1 can inhibit the phosphorylation
and the activity of the DNA-dependent protein kinase (DNA-
PK), a key enzyme for the double-strand breaks (DSBs) repair
(Lu et al., 2016; Lo et al., 2017). Together with other oncoproteins
(EBNA1 and EBNA2), LMP1 can also increase the cellular levels
of ROS and alter the mitotic checkpoint (Gruhne et al., 2009). As
a matter of fact, ROS levels fluctuate (due to inefficient oxidative
phosphorylation) in EBV-infected cells. Increases or decreases in
the level of ROS seem to favor carcinogenesis (Gruhne et al., 2009;
Lu et al., 2016).
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Moreover, by disrupting the physical interaction between
AMPK and DNA-PK, LMP1 can reduce AMPK phosphorylation
and change its subcellular location after irradiation (Lu et al.,
2016). AMPK is a crucial energy sensor that, as a negative
regulator of glycolysis, helps the maintenance of cellular energy
homeostasis. However, it is also a regulator of the DDR pathway
in response to genomic stress. A decrease in AMPK activity is
associated with resistance to irradiation-induced apoptosis, and
thus to a poorer clinical outcome in NPC patients treated with
radiation therapy. At the same time, the reactivation of AMPK,
which may be obtained via AMPK activators, significantly
promotes radiosensitivity and could be efficiently used for
facilitating NPC radiotherapy (Lu et al., 2016).
EBV-DRIVEN CARBOHYDRATE
METABOLIC ALTERATIONS IN
LYMPHOMAS
EBV is a powerful lymphocyte growth-promoter and
transformer. It is etiologically linked to many lympho-
proliferative disorders and malignant lymphomas including
BL, Hodgkin lymphoma, some types of diffuse large B cell
lymphomas, and rare B lymphomas of the immunocompromised
state, as well as T/NK cell lymphoproliferative disorders,
for example, extranodal NK/T-cell lymphoma, nasal type
(Shannon-Lowe et al., 2017).
The part played by EBV in these tumors’ pathogenesis shares
some common points with that of EBV in NPC, including
the mostly LMP1-driven metabolic disruption, which plays an
important role in this case as well (Figure 2).
Glucose consumption, a hallmark of the Warburg effect, is
common to antigen or mitogen stimulated lymphocytes and
many B-lymphomas. This suggests the importance of a glycolysis-
based mechanism to support rapid lymphocyte proliferation
(Sariban-Sohraby et al., 1983; Sommermann et al., 2011). The
way this mechanism works is now beginning to be understood
(Sariban-Sohraby et al., 1983) and it is becoming clear how some
key genes (such as PI3K and TP53) probably play a crucial role in
it (Calvo-Vidal and Cerchietti, 2013).
Moreover, recent findings suggest that, especially during cell
proliferation and stress conditions, other substrates, besides
glucose, can become an important driving force for glycolysis,
this including nucleotide biosynthesis and glycine-folate
metabolism (Calvo-Vidal and Cerchietti, 2013).
As for nucleotide biosynthesis, one of the major requirements
for cell proliferation is the production of DNA and RNA
which needs the incorporation of about ten carbon atoms
for each nucleotide (9 for pyrimidines and 10 for purines,
respectively; Calvo-Vidal and Cerchietti, 2013). Five of these
atoms are derived from the ribose-phosphate pathway. If an
exogenous source of nucleotides is available, nucleotides can be
obtained by the salvage pathway as well. Nevertheless, when
there is an important increase in lymphocytes’ proliferation, the
number of nucleotides required is so high that the de novo
pathway must be activated (Calvo-Vidal and Cerchietti, 2013).
One proof of this can be the increased activity of the inosine
monophosphate dehydrogenase (IMPDH) activity, an enzyme
catalyzing a fundamental reaction of de novo purine biosynthesis
(nicotinamide adenine dinucleotide-dependent oxidation of
inosine monophosphate to xanthosine monophosphate), which
has been demonstrated in T-cell and B-cell leukemias and
lymphomas (Hovi et al., 1976; Nagai et al., 1991; Calvo-Vidal and
Cerchietti, 2013).
A possible source for purine synthesis is glycine, which
can supply carbon both to the DNA itself (together with
nitrogen) and to folates that are required for the synthesis
of purines and thymidine. It has been shown that cancer cell
proliferation is associated to in vitro glycine consumption (while
its depletion prolongs the cell cycle) and that the upregulation of
its endogenous mitochondrial production is required for cancer
cells’ metabolic reprogramming (Jain et al., 2012; Calvo-Vidal and
Cerchietti, 2013).
It has also been suggested that the glycine pathway plays
a role in genetic and epigenetic cell integrity. Its alterations
may then affect the response of lymphoma cells to therapy,
both chemotherapy and epigenetic-targeted one (Calvo-Vidal
and Cerchietti, 2013; Vazquez et al., 2013).
The NF-kB pathway has been hypothesized as another
pathway involved in glucose import. NF-kB activation is
typical of transformed B lymphocytes including Herpes virus
transformed lymphoblasts, mimicking antigen co-receptor
signaling in B-lymphocytes (Kawauchi et al., 2008; Krawczyk
et al., 2010). NF-kB and its regulatory upstreaming protein
inhibitor of nuclear factor kappa B kinase subunit beta (IKBKB)
transcription can probably favor lymphoma cell survival by
promoting the increase of GLUT proteins on the plasma
membrane via AKT (Sommermann et al., 2011).
Glucose import across the lymphocyte cell membrane, in
fact, is mostly facilitated by GLUT proteins, the levels of which
can be regulated by some oncogenes and tumor suppressors.
For example, MYC and RAS induce GLUT1 mRNA (Osthus
et al., 2000), while p53 suppresses GLUT1, 3, and 4 expression
(Schwartzenberg-Bar-Yoseph et al., 2004). PI3K instead increases
both GLUT1 and GLUT3 expression (by inducing their mRNA
through the HIF1A pathway), and GLUT4 translocation to the
plasma membrane (moving from the storage vesicles under the
effect of AKT activation) in B lymphocytes (Zelzer et al., 1998;
Mîinea et al., 2005; Satoh, 2014) and probably in T-cells as well
(Wieman et al., 2007).
Taken together, these findings suggest that NF-kB signaling,
increasing the glucose import, supports proliferation and
resistance of cancer cells (Sommermann et al., 2011) and that
EBV has an important role in its activation (Gewurz et al.,
2011). As a matter of fact, the inhibition of the NF-kB pathway
in the EBV transformed B-cells lowers the glucose uptake to
the point of triggering its autophagy-induced death. When NF-
kB is inhibited, an alternate carbon source can overcome the
effect on autophagy and cell death, whereas autophagy inhibitors
accelerate them (Pujals et al., 2015).
HIF1A is another important factor which has been implied
both in epithelial and B-cell derived cancers in EBV infection
(Cuninghame et al., 2014). As the name says, this factor is
typically expressed in hypoxic conditions by normal cells to adapt
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to the hostile environment. It can also be expressed in tumor
cells enhancing glycolysis and activating MYC. In addition,
the stabilization of HIF1A and its translocation to the nucleus
can upregulate genes involved in cell growth, survival, and
angiogenesis (Cuninghame et al., 2014).
It has been wondered whether the increased expression
of HIF1A in cancer cells is a consequence of the necessity
for adaptation to the hypoxic tumor microenvironment (Lo
et al., 2013, 2015) or it is an intrinsic initiating event of the
tumor development. The fact that EBV infected B cells show
upregulation of HIF1A protein expression seems to validate the
latter hypothesis (Wakisaka et al., 2004; Lo et al., 2013, 2015; Xiao
et al., 2014; Sung et al., 2016). The proteins that increase HIF1A
expression are different in the different latency patterns: LMP1
stimulates HIF1A transcriptional activity through the p42/44
MAPK pathway (Wakisaka et al., 2004; Lo et al., 2013, 2015; Sung
et al., 2016) and contributes to its stabilization (Kondo et al., 2006;
Lo et al., 2013, 2015); both LMP1 and EBNA-1 upregulate HIF1A
and its downstream targets, IL-8 and VEGF (O’Neil et al., 2008;
Lo et al., 2013, 2015, 2017); EBNA-3s, which are expressed in
lymphatic chronic leukemia (LCL), bind the prolyl hydroxylase
enzymes (PHD1 and PHD2), blocking their phosphorylating
activity and thus stabilizing HIF1A (the complex HIF1, composed
of HIF1A and ARNT, is regulated by proteolysis of its α-subunits,
mediated by the oxygen-dependent hydroxylation of specific
prolyl residues; Appelhoff et al., 2004; Darekar et al., 2012; Lo
et al., 2013, 2015, 2017).
LIPID METABOLISM ALTERATION
Lipids are a wide group of diverse hydrophobic molecules
including triacylglycerides, phosphoglycerides, sphingolipids,
and sterols. Lipids are involved in cellular functions as both
structural components and as signaling factors (Santos and
Schulze, 2012). As for the structural role, fatty acids are used
for the synthesis of triacylglycerides, while phosphoglycerides,
sphingolipids, and sterols represent the principal components of
the plasma membrane and of other cellular membranes (Santos
and Schulze, 2012). As for the role in signaling, lipids can function
as hormones and as second messengers (Santos and Schulze,
2012). Therefore, lipid metabolism abnormalities in cancer cells
substantially affect membrane constitution, energy production,
and cellular signaling (Santos and Schulze, 2012; Hashmi et al.,
2015).
These alterations have been demonstrated both in NPC (Daker
et al., 2013) and in lymphomas (Ambrosio et al., 2012).
One common lipid metabolism alteration in EBV infection
is the increased expression of fatty acid synthase (FASN), an
enzyme that plays a key role in the cell endogenous fatty acid
synthesis (FAS) mediating the multiple condensation reaction
between malonil-CoA and acetyl-CoA molecules which leads to
the palmitate FAS (Figure 2). In particular, the transcription
factor immediate-early (IE) protein BRLF1 (R) – an inductor of
the lytic form of EBV infection – can activate FASN expression
through a p38 stress MAPK-dependent mechanism. At the same
time, BRLF1 can favor directly or indirectly the transcription of
other early viral promoters, including the EBV IE gene, BZLF1
(Z), that could have a role in increasing FAS too (Li et al., 2004).
De novo FAS is physiologically very active during the
embryological and fetal life (especially in the lung development
since FAs are used for synthesizing the surfactant) and in adult
females under hormone stimulation during the menstrual cycle,
being useful to the thickening of the endometrial wall, and to
the supply of milk with fatty acids during lactation. As for the
other tissues, a high-level FASN expression is normally limited
to liver, brain, lung, and adipose tissue in adults, as the main
lipid income for the cell comes from circulating lipids (Weiss
et al., 1986; Pizer et al., 1997; Wagle et al., 1999; Kusakabe
et al., 2000; Anderson et al., 2007). FASN expression can be
increased, though, in human epithelial cells infected with EBV
in its lytic form (Li et al., 2004) and in cancer cells (Lo et al.,
2017). In cancer, fatty acids, whatever the levels of circulating
triglycerides, are preferentially obtained by the activation of
FASN gene products in order to engage a de novo synthesis
of palmitate as opposed to what normally happens in healthy
cells of well-nourished adult individuals, which tend to rely on
fatty acids obtained from the diet (Menendez and Lupu, 2007;
Lo et al., 2017). A FAS increase, mediated by FASN increased
expression, has been demonstrated in breast cancer (especially
HER2+ one; Yoon et al., 2007), prostate cancer (Swinnen et al.,
2000), colorectal cancer (Li et al., 2000), and recently also in
BL, where it seems to be related to EBERs’ expression levels
(Ambrosio et al., 2012). One important confirmation to these
findings is that the FASN-driven tumorigenesis in EBV-infected
cells can be efficiently blocked by the use of FASN inhibitors (Li
et al., 2004).
As we have seen, tumor cells shift their metabolism to
aerobic glycolysis. However, aerobic glycolysis diverts citrate
away from the mitochondrial Krebs, which is necessary for FAS.
To promote aerobic glycolysis and FAS at the same time in rapidly
proliferating cells, glutamine needs to be rapidly replenished into
the tri-carboxylic acid (TCA) cycle (Lo et al., 2017). Glutamine
is an amino acid which supplies alternative intermediates for
TCA cycle. It is transported into cells through the SLC1A5
transporter, and then converted through an anaplerotic reaction
to α-ketoglutarate (Daye and Wellen, 2012; Lo et al., 2013, 2015;
Altman et al., 2016). It has been noticed that many cancer
cells use glutamine for oxidative phosphorylation, FAS, and
protein synthesis, and that γ-herpesviruses, including EBV, can
induce glutaminolysis. Specifically, LMP1 was found to increase
glutamine uptake and to induce elevate levels of intracellular
glutamate in EBV-infected nasopharyngeal epithelial cells (Lo
et al., 2013, 2015, 2017).
One key gene that has been related both to carbohydrate and
to lipid metabolic dysregulation in lymphomas is MYC (Lo et al.,
2017). MYC is a very well-known oncogene that contributes to
tumorigenesis by regulating key genes implicated in patterns that
converge to boost cellular growth and proliferation (Dang, 2013).
Its effects can be both direct (increase of energetic supplies) and
indirect (regulation of ribosomal and mitochondrial biosynthesis,
glucose, glutamine, and lipid metabolism; Dang, 2013; Lo et al.,
2017). Although the role of MYC in lymphomas’ lipids regulation
has not been completely elucidated yet (Eberlin et al., 2014),
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the analysis of lipid pattern expression has shown different
profiles between the MYC overexpressing ones and the others.
How this is obtained is still under investigation: according to
the most recent analyses, MYC could be implied in increasing
the FAS and the cell supply of acetyl-CoA, necessary for
lipid synthesis and nuclear histone acetylation (Morrish et al.,
2010).
Of interest, an aberrant MYC expression in EBV-infect
lymphoma cells has been seen, both in BL and other lymphomas
(Bultema et al., 2009; Fish et al., 2014). The concomitance
of EBV infection and MYC aberrant expression may suggest
either a cooperative role, or a mutual compensation driving
lymphomagenesis (e.g., early role for EBV and subsequent
acquisition of MYC aberrations). In LCL EBV-infected cells, for
example, EBNA2 activates MYC transcription (Kaiser et al., 1999)
via the EBV super-enhancers (ESEs; Zhou et al., 2015; Liang et al.,
2016), a cluster of genes binding to many different EBNAs and
transcriptional factors playing a role in LCL proliferation and
survival (Lo et al., 2017). EBNA3 and EBV miRNAs seem to play a
role as well in this process, which is currently under investigation
(Bajaj et al., 2008; Lo et al., 2017).
CLINICAL IMPLICATIONS
Since metabolic shift is a consistent aberration differentiating
neoplastic from normal cells, it is conceivable that interference
with that process may represent an effective therapeutic strategy.
EBV was demonstrated to be highly efficient in reprogramming
infected cell metabolism toward amplified anabolism. For this
reason, it represents a powerful strategy to identify key enzymes
involved in this process and consider them as cancer metabolism
drug targets (Figure 2; Galluzzi et al., 2013; Singh et al.,
2015).
Because EBV was demonstrated to deregulate glycolysis, anti-
glycolytic therapy might look as a promising opportunity in
the management of EBV-related cancers (Xiao et al., 2014).
Unfortunately, the inhibition of glycolytic enzymes may increase
the risk of adverse events such as hypoglycorrhachia. To
overcome this limit, it might be possible to target glucose
transporters and glycolytic enzymes that are preferentially used
by cancer cells compared with normal cells (Hay, 2016). Another
possible solution is to use anti-diabetic drugs that do not cause
hypoglycemia, such as metformin. Metformin has been found
to induce G1 cell-cycle arrest and inhibit the proliferation of
neoplastic cells (Anisimov et al., 2005; Libby et al., 2009; Cairns
et al., 2011; Lo et al., 2013, 2015; Lei et al., 2017). The therapeutic
value of metformin in solid tumors has been confirmed by many
clinical trials and is worthy of further investigation in the context
of hematological malignancies (Lo et al., 2013, 2015; Chae et al.,
2016; Gong et al., 2016).
Regarding the induction of HIF1A expression, topotecan
and bortezomib, two drugs that inhibit HIF1A translation and
transactivation, respectively, have been FDA-approved for the
treatment of lymphoid and solid cancers (Kummar et al., 2011;
Lo et al., 2013, 2015, 2017; Raedler, 2015). Ganetespib, a drug
that inhibits HIF1A stability, is currently being evaluated in a
Phase III trial for solid tumors (Lo et al., 2013, 2015, 2017;
Jhaveri and Modi, 2015) while novel HIF1A inhibitors are under
development. Agents that interfere with some of the downstream
effectors of HIF1A, including VEGF and carbonic anhydrase
IX, have been designed as well. Carbonic anhydrase can, in
fact, maintain the intracellular pH in a range that is compatible
with cell proliferation while it lowers the microenvironmental,
extracellular, pH conferring a survival advantage to tumor cells
growing in a hypoxic and acidic microenvironment (Chiche
et al., 2009). Agents decreasing the ROS levels in the cells, in
particular superoxide dismutase mimetics, have also been shown
to reduce HIF1A expression in experimental cancer settings
(Batinic-Haberle et al., 2010).
The AMPK activator 5-aminoimidazole-4-carboxamide
ribonucleotide formyl-transferase/IMP cyclohydrolase
(ATIC, formerly named AICAR) has been shown to inhibit
neoplastic cell growth and potentiate the cytotoxic effects of
chemotherapeutic drugs in different kind of cancers (Rattan
et al., 2005; Lo et al., 2013, 2015).
As for FAS, several FASN inhibitors have been investigated
in vitro and xenograft studies and preliminary results show them
to have both a killing tumor direct effect and a sensitizing effect
to other cancer common therapies, e.g., 5-FU and trastuzumab
(Pizer et al., 1998; Kridel et al., 2004; Vázquez et al., 2008).
CONCLUSION
Oncoviruses, including EBV, can reprogram host cell metabolism
to support viral persistence and tumor initiation. In the
presence of pre-existing or acquired genetic mutations, the
virus may indeed enable malignant transformation. In the
case of some aggressive B-NHL (i.e., DLBCL and endemic
BL), it is currently thought that genetic aberration such as
MYC rearrangements would occur in an EBV-positive memory
cell re-entering the germinal enter reaction. Remarkably,
this model is compatible with “hit and run” hypothesis.
In fact, despite allowing tumor initiation, viral particles can
be lost during tumor progression, thus not diminishing the
importance of viral contribution. Recent evidence shows that
tumors apparently negative for EBV do carry reminiscence
of a previous infections in terms of both residual viral
DNA or miRNAs (Mundo et al., 2017). The metabolic shift
as well as the anti-apoptotic phenotype would facilitate the
complete acquisition of the malignant phenotype in EBV-infected
cells.
Currently, a number of metabolism-interfering drugs are
under evaluation in clinical trials, some of which have been
approved by the FDA for cancer treatment. Hopefully, it will be
possible to combine them with conventional chemotherapies, as
well as with the newest targeted agents to increase anti-tumor
efficacy while containing treatment toxicity. Lastly, the clear
evidence that oncoviruses, and specially EBV, have a relevant
role in the establishment of malignant lymphomas (Ambrosio
et al., 2014a), should prompt current research to improve the
vaccination strategies against these common pathogens as it
happened for HPV.
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